Advertisement

Topics

DAIICHI SANKYO EUROPE GmbH and SHARE Company Profile

13:50 EDT 24th September 2017 | BioPortfolio

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than 5.9 billion EUR in fiscal year 2008, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of: cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs. For more information, please visit: http://www.daiichi-sankyo.eu


News Articles [3630 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo, Boston Pharmaceuticals sign deal for selective RET inhibitor for solid tumors

Daiichi Sankyo and Boston Pharmaceuticals have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

Tokyo, Japan, Basking Ridge, NJ, and Munich, Germany – (August 29, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (F...

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

TOKYO (Reuters) - Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca, following speculation that sent its share price soaring as much ...

AstraZeneca sought to buy Japan's Daiichi Sankyo last year: report

TOKYO (Reuters) - Britain's AstraZeneca PLC offered to buy peer Daiichi Sankyo Co Ltd last year, a business magazine reported on Thursday, sending the Japanese drugmaker's share price soaring as much ...

MD Anderson, Daiichi Sankyo Partner to Develop AML Treatments

The University of Texas MD Anderson Cancer Center and Daiichi Sankyo said today they plan to develop novel therapies for acute myeloid leukemia (AML) through a multi-year collaboration whose value was...

Daiichi Sankyo settles US products liability litigation

Japanese pharma major Daiichi Sankyo (TYO: 4568) and its US subsidiary have agreed to enter into a…

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center collaborate

Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the tre...

DAIICHI SANKYO EUROPE GmbH Release: New Sub-Analysis Data Highlights The Benefit Of LIXIANA (Edoxaban) Over Warfarin In NVAF Patients According To More Comprehensive Stroke Risk Scoring

  Life Sciences Jobs   ...

Drugs and Medications [54 Associated Drugs and Medications listed on BioPortfolio]

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Alcohol prep pad [Büttner-Frank GmbH]

La prairie switzerland [Juvena Produits de Beaute GMBH]

Package.Label Principle Display Panel

Purax pure pads [Purax International GmbH]

PURAX Pure Pads Anti-Perspirant Spray

PubMed Articles [655 Associated PubMed Articles listed on BioPortfolio]

Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa?

The Europe 2020 strategy and recently ratified Paris agreement are the main documents in the European Union (EU) involving energy and climate policy. Therefore, the aim of this paper is to reveal the ...

Pulled-out locking screw re-screwed spontaneously in anterior cervical decompression and fusion with the zero-profile implant system: A case report.

The zero-profile, standalone device (Zero-P, Synthes GmbH, Switzerland) has been reported to be an effective and safe treatment method with similar clinical outcomes compared with plate. Instrumental ...

Country-specific and individual determinants of dizziness in Europe: results from the Survey of Health Ageing and Retirement in Europe (SHARE).

Dizziness is one of the most common complaints amongst older persons and has relevant consequences for functioning. However, the epidemiological findings on dizziness are scarce and inconsistent and p...

Balancing Europe's wind power output through spatial deployment informed by weather regimes.

As wind and solar power provide a growing share of Europe's electricity1, understanding and accommodating their variability on multiple timescales remains a critical problem. On weekly timescales, var...

Binge drinking and well-being in European older adults: do gender and region matter?

We aimed to describe gender and region differences in the prevalence of binge drinking and in the association between binge drinking and well-being, among older adult Europeans. This is a cross-sectio...

Clinical Trials [690 Associated Clinical Trials listed on BioPortfolio]

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Hong Kong proposed this non-interventional study (NIS)...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) ...

Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this non-i...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non-valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this post-...

Companies [1744 Associated Companies listed on BioPortfolio]

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi-Sankyo

More Information about "DAIICHI SANKYO EUROPE GmbH and SHARE" on BioPortfolio

We have published hundreds of DAIICHI SANKYO EUROPE GmbH and SHARE news stories on BioPortfolio along with dozens of DAIICHI SANKYO EUROPE GmbH and SHARE Clinical Trials and PubMed Articles about DAIICHI SANKYO EUROPE GmbH and SHARE for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DAIICHI SANKYO EUROPE GmbH and SHARE Companies in our database. You can also find out about relevant DAIICHI SANKYO EUROPE GmbH and SHARE Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...


Corporate Database Quicklinks



Searches Linking to this Company Record